ABEONA THERAPEUTICS INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.
Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
Analysts updated ratings for five stocks: Rocket Pharmaceuticals (RCKT) was upgraded to Buy with a $9 target due to FDA confidence in its Danon disease study. Copart (CPRT) was downgraded to Hold with a $36 target due to weak insurance volumes and rising costs. Pegasystems (PEGA) was downgraded to Neutral with a $47 target due to AI-related disruption. Abeona Therapeutics (ABEO) was initiated with a Buy and $17 target due to strong gene therapy prospects. Fluence Energy (FLNC) was downgraded to
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ABEO (ABEONA THERAPEUTICS INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ABEO coverage spans earnings, regulation and sector analysis.
In the last 30 days, ABEO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($88K). The most active reporter was Alvino Mark with 1 filing.
New coverage may lift the stock as investors price in the $17 target.
First approved therapy for a rare disease could drive niche sales.
Buy initiation could boost the stock.
Approval unlocks royalty stream and milestone payments, supporting higher valuation.
Positive catalyst likely to boost ABEO share price.
AlphAI scores every news story that mentions ABEO with an AI model for sentiment and relevance, and aggregates insider trades from ABEONA THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.
3 min readSeveral biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
3 min readAnalysts updated ratings for five stocks: Rocket Pharmaceuticals (RCKT) was upgraded to Buy with a $9 target due to FDA confidence in its Danon disease study. Copart (CPRT) was downgraded to Hold with a $36 target due to weak insurance volumes and rising costs. Pegasystems (PEGA) was downgraded to Neutral with a $47 target due to AI-related disruption. Abeona Therapeutics (ABEO) was initiated with a Buy and $17 target due to strong gene therapy prospects. Fluence Energy (FLNC) was downgraded to
2 min readCantor Fitzgerald raised its price target on Abeona Therapeutics (NASDAQ:ABEO) to $30 from $28, citing its partner Ultragenyx's drug approval. Abeona is eligible for royalties and milestone payments. Q2 2026 revenue was $11.4M, below estimates, with a net loss of $20.2M. Roth/MKM initiated coverage with a Buy rating and $17 target.
2 min readAbeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.
2 min readAbeona Therapeutics (ABEO) reported Q2 revenue of $11.4M, up 31% from Q1, driven by its gene therapy ZEVASKYN. The company treated 12 patients, with 5 in Q2 and 3 more in Q3 to date. It secured a new technology add-on payment from CMS. However, net loss widened to $20.2M, and cancellations due to manufacturing issues were noted.
3 min readAbeona Therapeutics reported treating 12 patients since launch, with 5 in Q2 2026, but revenue recognized for only 4 due to manufacturing variability. It activated 7 qualified treatment centers by year-end goal. Q2 gross margin was 63%, with normalized 85% to 90% expected. Cash was $146.8M at June 30, 2026. CMS NTAP starts Oct 1, 2026.
6 min readAbeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.
4 min readAbeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.
4 min readABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau
4 min read
